Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ACXP Acurx Pharmaceuticals

Watchlist
3.500
-0.010-0.28%
Close  02/03 16:00 ET
High
3.610
Open
3.570
Turnover
85.45K
Low
3.470
Pre Close
3.510
Volume
23.95K
Market Cap
40.57M
P/E(TTM)
Loss
52wk High
4.850
Shares
11.59M
P/E(Static)
Loss
52wk Low
2.330
Float Cap
28.25M
Bid/Ask %
0.00%
Historical High
8.740
Shs Float
8.07M
Volume Ratio
0.35
Historical Low
2.330
Dividend TTM
--
Div Yield TTM
--
P/B
4.16
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.30%
Amplitude
3.99%
Avg Price
3.567
Lot Size
1
Float Cap
28.25M
Bid/Ask %
0.00%
Historical High
8.740
Shs Float
8.07M
Volume Ratio
0.35
Historical Low
2.330
Dividend TTM
--
P/B
4.16
Dividend LFY
--
Turnover Ratio
0.30%
Amplitude
3.99%
Avg Price
3.567
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
CEO: Mr. David P. Luci
Market: NASDAQ
Listing Date: 06/25/2021
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist